Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Debt (2016 - 2025)

Historic Total Debt for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $16.9 million.

  • Northwest Biotherapeutics' Total Debt fell 4361.28% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 4361.28%. This contributed to the annual value of $22.0 million for FY2024, which is 2551.19% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Total Debt stood at $16.9 million, which was down 4361.28% from $18.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Total Debt high stood at $358.6 million for Q1 2021, and its period low was $16.6 million during Q1 2025.
  • For the 5-year period, Northwest Biotherapeutics' Total Debt averaged around $91.7 million, with its median value being $29.5 million (2023).
  • In the last 5 years, Northwest Biotherapeutics' Total Debt skyrocketed by 286182.06% in 2021 and then crashed by 7868.11% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Total Debt stood at $131.9 million in 2021, then crashed by 34.4% to $86.6 million in 2022, then plummeted by 65.92% to $29.5 million in 2023, then dropped by 25.51% to $22.0 million in 2024, then fell by 23.3% to $16.9 million in 2025.
  • Its Total Debt stands at $16.9 million for Q3 2025, versus $18.3 million for Q2 2025 and $16.6 million for Q1 2025.